未分類
-
2022/08
Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. will give a pitch presentation in front of Sr SF Investors @UC Berkeley at the PITCH GLOBAL event on August 20 (via Zoom).
-
2022/08Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. gave a pitch presentation at the Pitch to CVC’s/VC’s’ angels +TDK&SK Group Thought Leadership that organized by the PITCH GLOBAL (www.pitchglobal.com).
-
2022/07Dr. Takuya Miyazaki, CEO of Red Arrow Therapeutics, Co., Ltd. attended the Venture Summit West from July 19-20, 2022, in Silicon Valley, CA. We look forward to meeting with top innovators and investors there.
-
2022/04Prof. Horacio Cabral from Red Arrow Therapeutics, Co., Ltd. presented promising preclinical data of RA-001 (pH-sensitive polymeric micelles loading IL-12) at AACR Annual Meeting 2022. RA-001 demonstrated a potent anti-tumor immunity in multiple tumor models. Furthermore, RA-001 showed high efficacy as monotherapy and in combination with immune checkpoint inhibitors.
See Poster Presentation -
2022/03Dr. Takuya Miyazaki, CEO from Red Arrow Therapeutics, Co. Ltd. joined a pitch event, namely, STEP to Biotech/Healthcare Startups powered by CIC/LINK-J. He performed two presentations to spread a company overview and to look for talented persons.
-
2022/02Red Arrow Therapeutics, Co. Ltd. will develop a pipeline by using AMED Seeds A grant. We aim to make proceedings on lead optimization by using this grant.
-
2021/12Red Arrow Therapeutics, Co. Ltd. closed their 1st seed round. They earned 0.8 M USD to develop their pipeline, IP and HR. They will look for additional fundings to earn 0.2-0.4 M USD by April.